{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T04:30:50Z","timestamp":1750307450251,"version":"3.41.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T00:00:00Z","timestamp":1746144000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T00:00:00Z","timestamp":1746144000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100016275","name":"Seoul National University Bundang Hospital","doi-asserted-by":"publisher","award":["02-2023-0024"],"award-info":[{"award-number":["02-2023-0024"]}],"id":[{"id":"10.13039\/100016275","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002551","name":"Seoul National University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002551","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastroenterol"],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Backgrounds<\/jats:title>\n            <jats:p>The disease course of inflammatory bowel disease (IBD) is highly variable; early and precise identification of patients with poor outcomes is crucial. We aimed to classify the long-term disease course of IBD using biochemical markers and evaluate the clinical factors associated with different disease courses.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>A latent class mixed model was employed to identify distinct trajectories of C-reactive protein (CRP) and fecal calprotectin (FCP) levels in 256 and 635 patients with Crohn\u2019s disease (CD) and ulcerative colitis (UC), respectively, from a tertiary hospital cohort. Multinomial logistic regression was used to evaluate the relationships between various trajectories and clinical variables.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Three trajectories were identified for CD and UC: class 1, early and sustained biochemical remission; class 2, delayed remission; and class 3, prolonged difficulty in achieving remission for &gt;\u20095 years. For patients with CD, early immunomodulator initiation was associated with a high likelihood of belonging to class 1 in the CRP trajectory analysis, whereas early advanced therapy increased the probability of belonging to class 1 in the FCP trajectory analysis. CRP trajectory analysis showed no significant associations in patients with UC. Younger age at diagnosis and early immunomodulator initiation were associated with higher odds of being in class 2 or 3, whereas current smoking was associated with a high likelihood of being in class 1 in the FCP trajectory analysis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Early aggressive medical treatment for CD may lead to long-term biochemical remission, whereas no similar association was observed in UC.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s00535-025-02244-w","type":"journal-article","created":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T13:01:39Z","timestamp":1746190899000},"page":"854-865","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of early aggressive treatment on long-term biochemical marker patterns in inflammatory bowel disease"],"prefix":"10.1007","volume":"60","author":[{"given":"Yu Kyung","family":"Jun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yonghoon","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheol Min","family":"Shin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young Soo","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nayoung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong Ho","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3440-2027","authenticated-orcid":false,"given":"Soyeon","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2657-0349","authenticated-orcid":false,"given":"Hyuk","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,2]]},"reference":[{"key":"2244_CR1","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","volume":"160","author":"D Turner","year":"2021","unstructured":"Turner D, Ricciuto A, Lewis A, et al. STRIDE-II: an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology. 2021;160:1570\u201383.","journal-title":"Gastroenterology"},{"key":"2244_CR2","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1097\/00054725-200606000-00013","volume":"12","author":"MR Konikoff","year":"2006","unstructured":"Konikoff MR, Denson LA. Role of fecal calprotectin as a biomarker of intestinal inflammation in inflammatory bowel disease. Inflam Bowel Dis. 2006;12:524\u201334.","journal-title":"Inflam Bowel Dis"},{"key":"2244_CR3","doi-asserted-by":"publisher","first-page":"74","DOI":"10.3109\/00365521.2014.987809","volume":"50","author":"T Sipponen","year":"2015","unstructured":"Sipponen T, Kolho K-L. Fecal calprotectin in diagnosis and clinical assessment of inflammatory bowel disease. Scand J Gastroenterol. 2015;50:74\u201380.","journal-title":"Scand J Gastroenterol"},{"key":"2244_CR4","doi-asserted-by":"publisher","first-page":"2779","DOI":"10.1016\/S0140-6736(17)32641-7","volume":"390","author":"J-F Colombel","year":"2017","unstructured":"Colombel J-F, Panaccione R, Bossuyt P, et al. Effect of tight control management on Crohn\u2019s disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet. 2017;390:2779\u201389.","journal-title":"Lancet"},{"key":"2244_CR5","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1097\/MIB.0000000000001082","volume":"23","author":"A Heida","year":"2017","unstructured":"Heida A, Park K, van Rheenen PF. Clinical utility of fecal calprotectin monitoring in asymptomatic patients with inflammatory bowel disease: a systematic review and practical guide. Inflam Bowel Dis. 2017;23:894\u2013902.","journal-title":"Inflam Bowel Dis"},{"key":"2244_CR6","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1053\/j.gastro.2022.12.007","volume":"164","author":"S Singh","year":"2023","unstructured":"Singh S, Ananthakrishnan AN, Nguyen NH, et al. AGA clinical practice guideline on the role of biomarkers for the management of ulcerative colitis. Gastroenterology. 2023;164:344\u201372.","journal-title":"Gastroenterology"},{"key":"2244_CR7","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1053\/j.gastro.2023.09.029","volume":"165","author":"AN Ananthakrishnan","year":"2023","unstructured":"Ananthakrishnan AN, Adler J, Chachu KA, et al. AGA clinical practice guideline on the role of biomarkers for the management of Crohn\u2019s disease. Gastroenterology. 2023;165:1367\u201399.","journal-title":"Gastroenterology"},{"key":"2244_CR8","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1016\/j.cgh.2007.09.002","volume":"5","author":"IC Solberg","year":"2007","unstructured":"Solberg IC, Vatn MH, H\u00f8ie O, et al. Clinical course in Crohn\u2019s disease: results of a Norwegian population-based ten-year follow-up study. Clin Gastroenterol Hepatol. 2007;5:1430\u20138.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2244_CR9","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1080\/00365520802600961","volume":"44","author":"IC Solberg","year":"2009","unstructured":"Solberg IC, Lygren I, Jahnsen J, et al. Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study). Scand J Gastroenterol. 2009;44:431\u201340.","journal-title":"Scand J Gastroenterol"},{"key":"2244_CR10","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1093\/ecco-jcc\/jjaa232","volume":"15","author":"IL Monstad","year":"2021","unstructured":"Monstad IL, Solberg IC, Cvancarova M, et al. Outcome of ulcerative colitis 20 years after diagnosis in a prospective population-based inception cohort from South-Eastern Norway, the IBSEN Study. J Crohns Colitis. 2021;15:969\u201379.","journal-title":"J Crohns Colitis"},{"issue":"2918\u201327","key":"2244_CR11","volume":"21","author":"N Constantine-Cooke","year":"2023","unstructured":"Constantine-Cooke N, Monterrubio-G\u00f3mez K, Plevris N, et al. Longitudinal fecal calprotectin profiles characterize disease course heterogeneity in Crohn\u2019s disease. Clin Gastroenterol Hepatol. 2023;21(2918\u201327): e6.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2244_CR12","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1093\/ecco-jcc\/jjaa173","volume":"15","author":"D Wintjens","year":"2021","unstructured":"Wintjens D, Bergey F, Saccenti E, et al. Disease activity patterns of Crohn\u2019s disease in the first ten years after diagnosis in the population-based IBD South Limburg Cohort. J Crohns Colitis. 2021;15:391\u2013400.","journal-title":"J Crohns Colitis"},{"key":"2244_CR13","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1038\/s41393-018-0169-9","volume":"56","author":"L Harvey","year":"2018","unstructured":"Harvey L. REDCap: web-based software for all types of data storage and collection. Spinal Cord. 2018;56:625.","journal-title":"Spinal Cord"},{"key":"2244_CR14","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1177\/2050640618784046","volume":"6","author":"C Reenaers","year":"2018","unstructured":"Reenaers C, Bossuyt P, Hindryckx P, et al. Expert opinion for use of faecal calprotectin in diagnosis and monitoring of inflammatory bowel disease in daily clinical practice. United European Gastroenterol J. 2018;6:1117\u201325.","journal-title":"United European Gastroenterol J"},{"key":"2244_CR15","doi-asserted-by":"publisher","first-page":"15374","DOI":"10.3748\/wjg.v20.i41.15374","volume":"20","author":"LM Spekhorst","year":"2014","unstructured":"Spekhorst LM, Visschedijk MC, Alberts R, et al. Performance of the Montreal classification for inflammatory bowel diseases. World J Gastroenterol. 2014;20:15374\u201381.","journal-title":"World J Gastroenterol"},{"key":"2244_CR16","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1093\/qjmed\/94.11.615","volume":"94","author":"J McLaren","year":"2001","unstructured":"McLaren J, Stimson RH, McRorie E, et al. The diagnostic value of anti-neutrophil cytoplasmic antibody testing in a routine clinical setting. QJM. 2001;94:615\u201321.","journal-title":"QJM"},{"key":"2244_CR17","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1053\/gast.2001.22546","volume":"120","author":"S Vermeire","year":"2001","unstructured":"Vermeire S, Joossens S, Peeters M, et al. Comparative study of ASCA (Anti\u2013Saccharomyces cerevisiae antibody) assays in inflammatory bowel disease. Gastroenterology. 2001;120:827\u201333.","journal-title":"Gastroenterology"},{"key":"2244_CR18","doi-asserted-by":"publisher","first-page":"43","DOI":"10.5217\/ir.2022.00029","volume":"21","author":"S-J Koh","year":"2023","unstructured":"Koh S-J, Hong SN, Park S-K, et al. Korean clinical practice guidelines on biologics for moderate to severe Crohn\u2019s disease. Intest Res. 2023;21:43.","journal-title":"Intest Res"},{"key":"2244_CR19","doi-asserted-by":"publisher","first-page":"339","DOI":"10.5217\/ir.2022.00135","volume":"21","author":"EM Song","year":"2023","unstructured":"Song EM, Na S-Y, Hong SN, et al. Treatment of inflammatory bowel disease\u2014Asian perspectives: the results of a multinational web-based survey in the 8th Asian Organization for Crohn\u2019s and Colitis meeting. Intest Res. 2023;21:339\u201352.","journal-title":"Intest Res"},{"key":"2244_CR20","doi-asserted-by":"publisher","first-page":"61","DOI":"10.5217\/ir.2022.00007","volume":"21","author":"S-Y Na","year":"2023","unstructured":"Na S-Y, Choi CH, Song EM, et al. Korean clinical practice guidelines on biologics and small molecules for moderate-to-severe ulcerative colitis. Intestinal Res. 2023;21:61\u201387.","journal-title":"Intestinal Res"},{"key":"2244_CR21","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1093\/ecco-jcc\/jjad089","volume":"17","author":"J Rev\u00e9s","year":"2023","unstructured":"Rev\u00e9s J, Mascarenhas A, Jos\u00e9 Temido M, et al. Early intervention with biologic therapy in Crohn\u00b4 s disease: how early is early? J Crohns Colitis. 2023;17:1752\u201360.","journal-title":"J Crohns Colitis"},{"key":"2244_CR22","doi-asserted-by":"publisher","first-page":"492","DOI":"10.4240\/wjgs.v8.i7.492","volume":"8","author":"V An","year":"2016","unstructured":"An V, Cohen L, Lawrence M, et al. Early surgery in Crohn\u2019s disease a benefit in selected cases. World J Gastrointest Surg. 2016;8:492\u2013500.","journal-title":"World J Gastrointest Surg"},{"key":"2244_CR23","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1146\/annurev.clinpsy.121208.131413","volume":"6","author":"DS Nagin","year":"2010","unstructured":"Nagin DS, Odgers CL. Group-based trajectory modeling in clinical research. Annu Rev Clin Psychol. 2010;6:109\u201338.","journal-title":"Annu Rev Clin Psychol"},{"key":"2244_CR24","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-020683","volume":"8","author":"H Lennon","year":"2018","unstructured":"Lennon H, Kelly S, Sperrin M, et al. Framework to construct and interpret latent class trajectory modelling. BMJ Open. 2018;8: e020683.","journal-title":"BMJ Open"},{"key":"2244_CR25","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1002\/(SICI)1097-0258(20000530)19:10<1303::AID-SIM424>3.0.CO;2-E","volume":"19","author":"H Lin","year":"2000","unstructured":"Lin H, McCulloch CE, Turnbull BW, et al. A latent class mixed model for analysing biomarker trajectories with irregularly scheduled observations. Stat Med. 2000;19:1303\u201318.","journal-title":"Stat Med"},{"key":"2244_CR26","first-page":"188","volume":"12","author":"WP Glasheen","year":"2019","unstructured":"Glasheen WP, Cordier T, Gumpina R, et al. Charlson comorbidity index: ICD-9 update and ICD-10 translation. Am Health Drug Benefits. 2019;12:188\u201397.","journal-title":"Am Health Drug Benefits"},{"key":"2244_CR27","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1038\/ajg.2015.120","volume":"110","author":"MH Mosli","year":"2015","unstructured":"Mosli MH, Zou G, Garg SK, et al. C-reactive protein, fecal calprotectin, and stool lactoferrin for detection of endoscopic activity in symptomatic inflammatory bowel disease patients: a systematic review and meta-analysis. Am J Gasteroenterol. 2015;110:802\u201319.","journal-title":"Am J Gasteroenterol"},{"key":"2244_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-230X-14-85","volume":"14","author":"MS Kwak","year":"2014","unstructured":"Kwak MS, Kim DH, Park SJ, et al. Efficacy of early immunomodulator therapy on the outcomes of Crohn\u2019s disease. BMC gastroenterol. 2014;14:1\u20136.","journal-title":"BMC gastroenterol"},{"key":"2244_CR29","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1111\/jgh.13169","volume":"31","author":"B Kim","year":"2016","unstructured":"Kim B, Cheon JH, Moon HJ, et al. Crohn\u2019s disease prognosis and early immunomodulator therapy: results from the CONNECT study. J Gastroenterol Hepatol. 2016;31:126\u201332.","journal-title":"J Gastroenterol Hepatol"},{"key":"2244_CR30","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1111\/apt.13363","volume":"42","author":"E Safroneeva","year":"2015","unstructured":"Safroneeva E, Vavricka S, Fournier N, et al. Impact of the early use of immunomodulators or TNF antagonists on bowel damage and surgery in Crohn\u2019s disease. Aliment Pharmacol Ther. 2015;42:977\u201389.","journal-title":"Aliment Pharmacol Ther"},{"key":"2244_CR31","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1093\/ibd\/izad149","volume":"30","author":"CCY Law","year":"2024","unstructured":"Law CCY, Tkachuk B, Lieto S, et al. Early biologic treatment decreases risk of surgery in crohn\u2019s disease but not in ulcerative colitis: systematic review and meta-analysis. Inflamm Bowel Dis. 2024;30:1080\u20136.","journal-title":"Inflamm Bowel Dis"},{"key":"2244_CR32","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1093\/ibd\/izac065","volume":"29","author":"A Buisson","year":"2023","unstructured":"Buisson A, Blanco L, Manlay L, et al. Top-down versus step-up strategies to prevent postoperative recurrence in Crohn\u2019s disease. Inflam Bowel Dis. 2023;29:185\u201394.","journal-title":"Inflam Bowel Dis"},{"key":"2244_CR33","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1053\/j.gastro.2013.10.027","volume":"146","author":"TD Walters","year":"2014","unstructured":"Walters TD, Kim M-O, Denson LA, et al. Increased effectiveness of early therapy with anti-tumor necrosis factor-\u03b1 vs an immunomodulator in children with Crohn\u2019s disease. Gastroenterology. 2014;146:383\u201391.","journal-title":"Gastroenterology"},{"key":"2244_CR34","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1136\/gut.2007.146357","volume":"57","author":"M Henriksen","year":"2008","unstructured":"Henriksen M, Jahnsen J, Lygren I, et al. C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease Results from a prospective population-based study. Gut. 2008;57:1518\u201323.","journal-title":"Gut"},{"key":"2244_CR35","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1097\/00054725-200409000-00026","volume":"10","author":"S Vermeire","year":"2004","unstructured":"Vermeire S, Van Assche G, Rutgeerts P. C-reactive protein as a marker for inflammatory bowel disease. Inflam Bowel Dis. 2004;10:661\u20135.","journal-title":"Inflam Bowel Dis"},{"key":"2244_CR36","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1111\/apt.13361","volume":"42","author":"V Chhaya","year":"2015","unstructured":"Chhaya V, Pollok R, Cecil E, et al. Impact of early thiopurines on surgery in 2770 children and young people diagnosed with inflammatory bowel disease: a national population-based study. Aliment Pharmacol Ther. 2015;42:990\u20139.","journal-title":"Aliment Pharmacol Ther"},{"key":"2244_CR37","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1111\/apt.13017","volume":"41","author":"V Chhaya","year":"2015","unstructured":"Chhaya V, Saxena S, Cecil E, et al. The impact of timing and duration of thiopurine treatment on colectomy in ulcerative colitis: a national population-based study of incident cases between 1989\u20132009. Aliment Pharmacol Ther. 2015;41:87\u201398.","journal-title":"Aliment Pharmacol Ther"},{"key":"2244_CR38","doi-asserted-by":"publisher","first-page":"2740","DOI":"10.1007\/s10620-018-5176-3","volume":"63","author":"A Vedamurthy","year":"2018","unstructured":"Vedamurthy A, Xu L, Luther J, et al. Long-term outcomes of immunosuppression-na\u00efve steroid responders following hospitalization for ulcerative colitis. Dig Dis Sci. 2018;63:2740\u20136.","journal-title":"Dig Dis Sci"},{"key":"2244_CR39","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1053\/j.gastro.2021.10.037","volume":"162","author":"S Ben-Horin","year":"2022","unstructured":"Ben-Horin S, Novack L, Mao R, et al. Efficacy of biologic drugs in short-duration versus long-duration inflammatory bowel disease: a systematic review and an individual-patient data meta-analysis of randomized controlled trials. Gastroenterology. 2022;162:482\u201394.","journal-title":"Gastroenterology"},{"key":"2244_CR40","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1093\/ibd\/izad149","volume":"30","author":"CC Law","year":"2024","unstructured":"Law CC, Tkachuk B, Lieto S, et al. Early biologic treatment decreases risk of surgery in Crohn\u2019s disease but not in ulcerative colitis: systematic review and meta-analysis. Inflam Bowel Dis. 2024;30:1080\u20136.","journal-title":"Inflam Bowel Dis"},{"key":"2244_CR41","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/S2468-1253(24)00034-7","volume":"9","author":"NM Noor","year":"2024","unstructured":"Noor NM, Lee JC, Bond S, et al. A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn\u2019s disease (PROFILE): a multicentre, open-label randomised controlled trial. Lancet Gastroenterol Hepatol. 2024;9:415\u201327.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2244_CR42","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1016\/S0140-6736(15)00068-9","volume":"386","author":"R Khanna","year":"2015","unstructured":"Khanna R, Bressler B, Levesque BG, et al. Early combined immunosuppression for the management of Crohn\u2019s disease (REACT): a cluster randomised controlled trial. Lancet. 2015;386:1825\u201334.","journal-title":"Lancet"}],"container-title":["Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-025-02244-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00535-025-02244-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-025-02244-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T12:04:04Z","timestamp":1750248244000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00535-025-02244-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,2]]},"references-count":42,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["2244"],"URL":"https:\/\/doi.org\/10.1007\/s00535-025-02244-w","relation":{},"ISSN":["0944-1174","1435-5922"],"issn-type":[{"type":"print","value":"0944-1174"},{"type":"electronic","value":"1435-5922"}],"subject":[],"published":{"date-parts":[[2025,5,2]]},"assertion":[{"value":"6 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}}]}}